Terms: = Thyroid cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Staging
48 results:
1. braf V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract] [Full Text] [Related]
2. How do
Mukhtar N; Alhamoudi K; Alswailem M; Alhindi H; Murugan AK; Alghamdi B; Alzahrani AS
Front Endocrinol (Lausanne); 2023; 14():1270796. PubMed ID: 37859987
[TBL] [Abstract] [Full Text] [Related]
3. Patterns of lymph node metastasis in level IIB and contralateral level VI for papillary thyroid carcinoma with pN1b and safety of low collar extended incision for neck dissection in level II.
Ning Y; Liu Y; Zeng D; Zhou Y; Ma L; Dong S; Sheng J; Wu G; Tian W; Cai Y; Li C
World J Surg Oncol; 2023 Aug; 21(1):249. PubMed ID: 37592337
[TBL] [Abstract] [Full Text] [Related]
4. Validation of dynamic risk stratification and impact of braf in risk assessment of thyroid cancer, a nation-wide multicenter study.
Pérez-Fernández L; Sastre J; Zafón C; Oleaga A; Castelblanco E; Capel I; Galofré JC; Guadalix-Iglesias S; De la Vieja A; Riesco-Eizaguirre G
Front Endocrinol (Lausanne); 2022; 13():1071775. PubMed ID: 36714606
[TBL] [Abstract] [Full Text] [Related]
5. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
Maurer E; Eilsberger F; Wächter S; Riera Knorrenschild J; Pehl A; Holzer K; Neubauer A; Luster M; Bartsch DK
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
[TBL] [Abstract] [Full Text] [Related]
6. Conventional papillary thyroid carcinoma with intraglandular lymphatic dissemination shows more aggressive features.
Lei Y; Feng S; Yu Q; Shen G; Yuan L; Huang W
Jpn J Clin Oncol; 2022 Nov; 52(11):1311-1320. PubMed ID: 35863013
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological Findings Associated With Cervical Lymph Node Metastasis in Papillary thyroid Microcarcinoma: A Retrospective Study in China.
Shi Y; Yang Z; Heng Y; Ju H; Pan Y; Zhang Y
Cancer Control; 2022; 29():10732748221084926. PubMed ID: 35285273
[TBL] [Abstract] [Full Text] [Related]
8. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract] [Full Text] [Related]
9. Differentiation of benign thyroid nodules from malignant thyroid nodules through miR-205-5p and thyroid-stimulating hormone receptor mRNA.
Zhou J; Cao L; Chen Z
Hormones (Athens); 2021 Sep; 20(3):571-580. PubMed ID: 33788150
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Pathology of Non-familial Follicular Epithelial-Derived thyroid cancer in Adults: From RAS/braf-like Tumor Designations to Molecular Risk Stratification.
Soares P; Póvoa AA; Melo M; Vinagre J; Máximo V; Eloy C; Cameselle-Teijeiro JM; Sobrinho-Simões M
Endocr Pathol; 2021 Mar; 32(1):44-62. PubMed ID: 33651322
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value of
van Ipenburg JA; Naus NC; Dubbink HJ; van Ginderdeuren R; Missotten GS; Paridaens D; Verdijk RM
Br J Ophthalmol; 2021 Oct; 105(10):1454-1461. PubMed ID: 33127831
[TBL] [Abstract] [Full Text] [Related]
12. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma.
Potter SL; Reuther J; Chandramohan R; Gandhi I; Hollingsworth F; Sayeed H; Voicu H; Kakkar N; Baksi KS; Sarabia SF; Lopez ME; Chelius DC; Athanassaki ID; Mahajan P; Venkatramani R; Quintanilla NM; Lopez-Terrada DH; Roy A; Parsons DW
Pediatr Blood Cancer; 2021 Jan; 68(1):e28741. PubMed ID: 33009870
[TBL] [Abstract] [Full Text] [Related]
13. Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary thyroid cancer.
Suh S; Goh TS; Kim YH; Oh SO; Pak K; Seok JW; Kim IJ
Endocrinol Metab (Seoul); 2020 Jun; 35(2):435-442. PubMed ID: 32615728
[TBL] [Abstract] [Full Text] [Related]
14. [Tumors of the thyroid gland. Proposal for the management and study of samples from patients with thyroid neoplasms].
Cameselle-Teijeiro JM; Bella Cueto MR; Eloy C; Abdulkader I; Amendoeira I; Matías-Guiu X; Sobrinho-Simões M
Rev Esp Patol; 2020; 53(1):27-36. PubMed ID: 31932006
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Parameters in Differentiated thyroid Carcinomas.
Cipriani NA
Surg Pathol Clin; 2019 Dec; 12(4):883-900. PubMed ID: 31672296
[TBL] [Abstract] [Full Text] [Related]
16. braf
Bakkar S; Macerola E; Aljarrah Q; Proietti A; Materazzi G; Basolo F; Miccoli P
Updates Surg; 2019 Dec; 71(4):701-704. PubMed ID: 31586312
[TBL] [Abstract] [Full Text] [Related]
17. CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer.
Kim MJ; Sun HJ; Song YS; Yoo SK; Kim YA; Seo JS; Park YJ; Cho SW
Sci Rep; 2019 Sep; 9(1):13288. PubMed ID: 31527616
[TBL] [Abstract] [Full Text] [Related]
18. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
19. Impact of braf V600E and TERT Promoter Mutations on Response to Therapy in Papillary thyroid cancer.
Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
[TBL] [Abstract] [Full Text] [Related]
20. In-Depth Proteomics Analysis to Identify Biomarkers of Papillary thyroid cancer Patients Older Than 45 Years with Different Degrees of Lymph Node Metastases.
Zhan S; Wang T; Wang M; Li J; Ge W
Proteomics Clin Appl; 2019 Sep; 13(5):e1900030. PubMed ID: 31148369
[TBL] [Abstract] [Full Text] [Related]
[Next]
